QCM
DYN icon

Quantinno Capital Management’s Dyne Therapeutics DYN Stock Holding History

Quantinno Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
51,489
+32,192
+167% +$599K ﹤0.01% 2447
2026
Q1 		$350K Buy
19,297
+6,704
+53% +$116K ﹤0.01% 2946
2025
Q4 		$246K Buy
12,593
+254
+2% +$4.81K ﹤0.01% 2947
2025
Q3 		$156K Buy
+12,339
New +$141K ﹤0.01% 2822

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Quantinno Capital Management's DYN Position: Q2 2026 in Review

Quantinno Capital Management increased its Dyne Therapeutics (DYN) stake by 167% in Q2 2026, buying an estimated $599K and bringing the position to 51,489 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2447.

Quantinno Capital Management first reported a position in DYN in Q3 2025 and has held it in 4 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Quantinno Capital Management held 51,489 shares of Dyne Therapeutics worth $1.14M as of Q2 2026.
  • Quantinno Capital Management bought 32,192 Dyne Therapeutics shares in Q2 2026, an estimated $599K.
  • Dyne Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2447 holding.
  • Quantinno Capital Management first reported a position in Dyne Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.